Immatics Enterprise Value Over E B I T D A from 2010 to 2025
| IMTXW Stock | USD 0.03 0 7.98% |
Enterprise Value Over EBITDA | First Reported 2010-12-31 | Previous Quarter (5.71) | Current Value (6.00) | Quarterly Volatility 7.04646742 |
Check Immatics Biotechnologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immatics Biotechnologies' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 15.7 M or Interest Income of 16.7 M, as well as many indicators such as Price To Sales Ratio of 15.53, Dividend Yield of 0.0 or PTB Ratio of 3.22. Immatics financial statements analysis is a perfect complement when working with Immatics Biotechnologies Valuation or Volatility modules.
Immatics | Enterprise Value Over E B I T D A |
Latest Immatics Biotechnologies' Enterprise Value Over E B I T D A Growth Pattern
Below is the plot of the Enterprise Value Over E B I T D A of immatics biotechnologies GmbH over the last few years. It is Immatics Biotechnologies' Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immatics Biotechnologies' overall financial position and show how it may be relating to other accounts over time.
| Enterprise Value Over E B I T D A | 10 Years Trend |
|
Enterprise Value Over E B I T D A |
| Timeline |
Immatics Enterprise Value Over E B I T D A Regression Statistics
| Arithmetic Mean | (11.16) | |
| Coefficient Of Variation | (63.13) | |
| Mean Deviation | 5.79 | |
| Median | (15.70) | |
| Standard Deviation | 7.05 | |
| Sample Variance | 49.65 | |
| Range | 24.826 | |
| R-Value | 0.71 | |
| Mean Square Error | 26.68 | |
| R-Squared | 0.50 | |
| Significance | 0 | |
| Slope | 1.05 | |
| Total Sum of Squares | 744.79 |
Immatics Enterprise Value Over E B I T D A History
About Immatics Biotechnologies Financial Statements
Immatics Biotechnologies investors use historical fundamental indicators, such as Immatics Biotechnologies' Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Immatics Biotechnologies. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Enterprise Value Over EBITDA | (5.71) | (6.00) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Immatics Stock Analysis
When running Immatics Biotechnologies' price analysis, check to measure Immatics Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immatics Biotechnologies is operating at the current time. Most of Immatics Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Immatics Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immatics Biotechnologies' price. Additionally, you may evaluate how the addition of Immatics Biotechnologies to your portfolios can decrease your overall portfolio volatility.